If you circle back to aprils 2023 webinar, 12 month follow up in phase2b trial 008 for categorical evidence of DMOAD on label is what we are waiting on for a deal to materialise in OA. Dec23, Jab 24, Feb 24 areas.
AND in the meantime, MPS trials to read out shortly with licensing agreement and a price for a course of Zilosul for the MPS asset is what we/I am waiting on. If our Zilosul price point in the rare disease area is significant, it will assist our price point for OA in the ranges Rennie wants 3-6k.
If you circle back to aprils 2023 webinar, 12 month follow up in...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.010(4.00%) |
Mkt cap ! $91.06M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.0¢ | 25.0¢ | $36.40K | 143.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40816 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 44646 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |